PRKAA2 and cancer: No significant equivalent sensitivity was noted for other cancer metabolic drugs such as PIK3CA (GDC0941 and AZD6482), GSK3A/B (SB 216763) inhibitors and PRKAA2 (AICAR and metformin) agonists (Supplementary Fig. 10).